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Herein, we evaluated the treatment strategy employing a therapeutic heterologous 
vaccine composed of antigens of Leishmania braziliensis associated with MPL adjuvant 
(LBMPL vaccine) for visceral leishmaniasis (VL) in symptomatic dogs naturally infected 
by Leishmania infantum. Sixteen dogs received immunotherapy with MPL adjuvant 
(n = 6) or with a vaccine composed of antigens of L. braziliensis associated with MPL 
(LBMPL vaccine therapy, n =  10). Dogs were submitted to an immunotherapeutic 
scheme consisting of 3 series composed of 10 subcutaneous doses with 10-day 
interval between each series. The animals were evaluated before (T0) and 90 days after 
treatment (T90) for their biochemical/hematological, immunological, clinical, and par-
asitological variables. Our major results showed that the vaccine therapy with LBMPL 
was able to restore and normalize main biochemical (urea, AST, ALP, and bilirubin) 
and hematological (erythrocytes, hemoglobin, hematocrit, and platelets) parameters. 
In addition, in an ex vivo analysis using flow cytometry, dogs treated with LBMPL 
vaccine showed increased CD3+ T lymphocytes and their subpopulations (TCD4+ and 
TCD8+), reduction of CD21+ B lymphocytes, increased NK cells (CD5−CD16+) and 
CD14+ monocytes. Under in  vitro conditions, the animals developed a strong anti-
gen-specific lymphoproliferation mainly by TCD4+ and TCD8+ cells; increasing in both 
TCD4+IFN-γ+ and TCD8+IFN-γ+ as well as reduction of TCD4+IL-4+ and TCD8+IL-4+ 
lymphocytes with an increased production of TNF-α and reduced levels of IL-10. 
Concerning the clinical signs of canine visceral leishmaniasis, the animals showed an 
2Roatt et al. Vaccine Therapy for CVL
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 217
inTrODUcTiOn
Visceral leishmaniasis (VL) is considered one of the most neglected 
of all the neglected diseases with endemic nature expanding 
in many peri-urban and urban areas of Brazil, Latin America, 
Europe, and other areas of the world (1, 2). VL is considered the 
most fatal form of the leishmaniasis if left untreated. In an attempt 
to control the disease, many strategies are used to interrupt 
parasite transmission, including elimination of seropositive dogs 
that act as reservoirs, use of insecticides for vector control and 
systematic treatment of human cases (3, 4). Several studies have 
shown the importance of the development of vaccines to control 
the disease (5–8); however, to date there are no vaccines that can 
be used in control programs against human or canine disease (9). 
Moreover, available treatment options are still far from a desirable 
efficacy due the fact that they are either toxic (antimonials and 
amphotericin B deoxycholate) or expensive (liposomal ampho-
tericin B) (10). The situation is even more complicated by the 
imminent emergence of resistant parasites to presently available 
anti-leishmanial drugs, mainly with monotherapy (miltefosine 
and paromomycin) (11). Thus, there is an urgent need to improve 
current drugs and promote investment in the discovery of new 
treatment schemes such as vaccines or immunomodulators 
(immunotherapy) to promptly induce an effective and protective 
immune response against the parasite (10).
Immunotherapy was first used against tegumentar leishma-
niasis, mainly in cutaneous and mucosal patients in Venezuela 
by Convit and colleagues (12, 13). In Brazil, Mayrink et al. (14) 
obtained 98% of clinical cure in patients with cutaneous leish-
maniasis using as treatment a vaccine composed of Leishmania 
amazonensis antigens plus Bacillus Calmette–Guerin (BCG) as 
adjuvant. Few studies have demonstrated the effectiveness of 
immunotherapy in visceral disease. Badaro and colleagues (15) 
showed the efficiency of IFN-γ in the treatment of some refrac-
tory patients to conventional chemotherapy. The same authors 
evaluated the combination of IFN-γ plus antimony (immuno-
chemotherapy) demonstrating that this combined therapy was 
effective in a preliminary trial in patients with refractory visceral 
and mucosal leishmaniasis to conventional antimonial chemo-
therapy (15).
More recently, a large number of studies have developed new 
protocols focused on immunochemotherapy to treat VL. In this 
context, the murine models have been employed using different 
strategies such as synthetic bacterial lipopeptide (Pam3cys), 
monoclonal antibodies (mAbs) against cytokine receptors or 
cytokines, dendritic cell-based treatment, and vaccines. All of 
these strategies are combined with chemotherapy using low dose 
or short course of an effective conventional drug or new candi-
dates (16–20). Dogs are considered one of the most important 
models for VL studies including vaccines and treatment tests and 
more recently has become even more relevant for the evaluation 
of immunotherapy and immunochemotherapy protocols. In 
this sense, vaccines associated with conventional chemotherapy 
have been employed demonstrating important results (21–23). 
Recently, Santiago and colleagues (24) evaluated the immuno-
therapeutic potential of P-MAPA, an immunomodulator in 
symptomatic dogs with VL. After this treatment, dogs showed 
significant improvement in clinical signs, decrease in IL-10, 
and increase in IL-2 and IFN-γ production, with reduction in 
cutaneous parasitism, demonstrating the effectiveness of immu-
notherapy in symptomatic VL disease (24).
In summary, many studies indicate that immunotherapy 
is a promising strategy for VL treatment mainly by the 
reestablishment of immunity. Thus, our study aimed to 
evaluate effect of using a heterologous therapeutic vaccine—
LBMPL—composed of Leishmania braziliensis antigens plus 
monophosphoryl lipid A, a detoxified form of the endotoxin 
lipopolysaccharide, and potent toll-like receptor 4 activator 
(25), as an immunotherapy strategy for treatment of VL in 
symptomatic dogs naturally infected by Leishmania infantum 
as experimental model.
MaTerials anD MeThODs
ethics statement
The study protocol was approved by the Ethical Committee for 
the Use of Experimental Animals of the Universidade Federal de 
Ouro Preto, Ouro Preto, MG, Brazil, under the protocol number 
2010/57. All experiments were performed according to the 
important reduction in the number and intensity of the disease signs; increase body 
weight as well as reduction of splenomegaly. In addition, the LBMPL immunotherapy 
also promoted a reduction in parasite burden assessed by real-time PCR. In the bone 
marrow, we observed seven times less parasites in LBMPL animals compared with 
MPL group. The skin tissue showed a reduction in parasite burden in LBMPL dogs 
127.5 times higher than MPL. As expected, with skin parasite reduction promoted by 
immunotherapy, we observed a blocking transmission to sand flies in LBMPL dogs 
with only three positive dogs after xenodiagnosis. The results obtained in this study 
highlighted the strong potential for the use of this heterologous vaccine therapy as an 
important strategy for VL treatment.
Keywords: heterologous vaccine therapy, immunotherapy, canine visceral leishmaniasis, L. infantum, immune 
response
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guidelines of the National Institutes of Health, USA. We made all 
efforts to minimize animal suffering.
study animals, inclusion criteria, and 
immunotherapy Protocol
In this study, 16 mixed breed adult dogs of both sexes, naturally 
infected with L. infantum and presenting at least three clinical 
signs related to the canine visceral leishmaniasis (CVL) (weight 
loss, dermatitis, and lymphadenopathy), were used. They were 
kindly provided by the owners after signing the informed con-
sent at the time of the animal retrieval by the Center for Zoonosis 
Control (Centro de Controle de Zoonoses) of Governador 
Valadares, Minas Gerais, Brazil, an important endemic area for 
VL. Dogs were maintained in individual enclosed kennels, with 
access to water and balanced canine feed ad libitum, belonging to 
the Kennel for Drug Trial and Vaccines for Leishmaniasis of the 
Universidade Federal de Ouro Preto, Minas Gerais, Brazil. They 
had direct contact with pen mates and received daily exercise in 
the facility. Moreover, there was environmental enrichment in 
the form of several toys in the interior of each cage. Furthermore, 
the animals were subjected to a standard quarantine protocol 
with broad spectrum anthelmintic and vaccinated against 
rabies (Tecpar, Curitiba, PR, Brazil) before the initiation of the 
immunotherapy protocol. The clinical criterion to select VL 
symptomatic dogs was according to Reis and colleagues (26). 
Moreover, we defined as inclusion criteria for this study posi-
tive serological tests for VL (ELISA and DPP®) as the Brazilian 
Ministry of Health recommends. Besides that, we associate the 
positive serological results with parasitological tests using bone 
marrow aspirates to demonstrate parasites in NNN/LIT culture 
or through real-time PCR. Only animals showing symptoms and 
positive serological and parasitological tests were included in the 
study.
Experimental dogs were divided into two groups: a group 
that received immunotherapy only with monophosphoryl 
lipid A adjuvant, considered the control group (MPL, n = 6) 
and a group that received immunotherapy using the vaccine 
composed by L. braziliensis promastigote protein associated 
with MPL as adjuvant (LBMPL, n = 10). The antigen compo-
nent of the LBMPL vaccine was previously evaluated by our 
research group demonstrating significant results as a prophy-
lactic vaccine in hamster and dog models of VL (5, 6, 27–31). 
For our study, we proposed to use a protocol used by Mayrink 
and colleagues that treat leishmaniasis in Brazil using vaccine 
therapy (14, 32). The animals were subjected to an immu-
notherapeutic scheme consisting of 3 treatment series, each 
series composed of 10 doses with increasing concentrations 
of the vaccine antigen [60–300 μg antigen protein + 5–25 μg 
of MPL (days 1–5) and 300 μg of antigen protein + 25 μg of 
MPL (days 6–10) in 1 mL of sterile 0.9% saline in first series; 
300 μg antigen protein + 25 μg of MPL in 1 mL of sterile 0.9% 
saline in second and third series by subcutaneous route and a 
10-day interval between each series]. For the MPL group, the 
adjuvant was used alone following the same scheme described 
for LBMPL group. The dogs were evaluated before (T0) and 
90  days (T90) after immunotherapy (150  days of the total 
experiment).
sample collection
Peripheral blood, bone marrow, and skin samples were collected 
from both groups of dogs before the onset of the treatment (day 
0 = T0) and 90 days after completion the immunotherapy proto-
col (day 150 = T90). The skin biopsies were performed with aid 
of the tranquilizer acepromazine (1.1 mg/kg) and local blockage 
with 1% xylocaine using a 5 mm “punch.” The skin samples were 
obtained from the middle portion of the ear and stored at −80°C 
until processing. Blood samples were collected according to 
described protocol (5) and stored at room temperature to per-
form the biochemical/hematological and immunophenotyping 
tests. Bone marrow samples were collected according to previous 
protocol (33) and stored at −80°C until processing.
Biochemical/hematological analysis and 
Ex Vivo immunophenotyping
The absolute count of lymphocytes in each sample was obtained 
using a BC-2800 VET auto hematology analyzer (Mindray, 
China). Erythrocytes and leukocytes were quantified using the 
same equipment, and the differential leukocyte counts were 
obtained by blood smear analysis after prior staining by routine 
methods. For normal range values of white blood cells (WBC) 
and red blood cells (RBC), 45 healthy dogs were used to create 
a normal range that was used in this study. The biochemical 
evaluations consisted of the liver function (dosage of the enzymes: 
alanine transaminase—ALT/GPT, aspartate aminotransferase—
AST/GOT, gamma-glutamyl transferase—γ-GT, alkaline 
phosphatase—ALP, and bilirubin); renal function (urea and 
creatinine) and proteinogram (total protein, albumin, globulin, 
and albumin/globulin ratio) tests. For the analysis, an Automatic 
Biochemical System (CELM SBA-200, Barueri, SP, Brazil) and 
commercials Labtest Kits (Labtest Diagnostica SA, Lagoa Santa, 
MG, Brazil) were used following the instructions described by 
the manufacturer.
The immunophenotyping of leukocytes (ex vivo) was performed 
according to de Almeida Leal et  al. (34) with minor modifica-
tions. Canine mAbs anti-CD3 PE (clone CA17.2A12), anti-CD4 
FITC (clone YKIX302.9), anti-CD8 AF647 (clone YCATE55.9), 
anti-CD21 PE (clone CA2.1D6), anti-CD14 RPE-Cy5 (TÜK4), 
anti-CD5 PE (clone YKIX322.3), and anti-human-CD16 
RPE-Cy5 (3G8) all purchased from Serotec, USA were used in an 
indirect immunofluorescence procedure in which pooled normal 
rat serum (diluted 1:6,000) was employed as the isotopic control. 
The results were expressed in absolute counts (cell number per 
cubic meter) through the product of the percentage of positive 
cells (CD3+, CD4+, CD8+, CD5−CD16+, and CD21+) within gated 
lymphocytes by absolute lymphocyte counts. The absolute counts 
for monocytes were obtained through the products of CD14+ 
cells within ungated leukocytes by the selection of the region of 
interest, based on morphometric and immunophenotypic graph-
ics of distribution CD14/FL3 versus side scatter.
In Vitro Proliferation and intracellular 
cytokines assays
The soluble L. infantum [MHOM/BR/1070/BH46 antigen soluble 
Leishmania infantum antigen (SLiAg)] was prepared as described 
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by Reis and colleagues (35) from promastigotes harvested from 
stationary phase in liver infusion tryptose cultures. The concen-
tration of protein in the SLiAg solution was adjusted to 1 mg/mL 
and stored at −80°C until required for assays.
The in  vitro proliferation assay was performed as described 
by Roatt and colleagues (5) with some modifications. Briefly, 
peripheral blood mononuclear cells (PBMCs) were isolated from 
20 mL of heparinized blood that had been layered onto 10 mL 
of Ficoll–Hypaque density gradient (Histopaque® 1.077; Sigma 
Chemical Co.) and centrifuged at 450 ×  g for 40  min at room 
temperature. The separated PBMCs were resuspended in RPMI 
1640 medium, homogenized, washed twice with RPMI 1640, 
centrifuged and finally resuspended in RPMI 1640 at 107 cells/
mL for labeling using carboxy fluorescein diacetate succinimidyl 
ester (CFSE, Molecular Probes, USA). Cells were resuspended 
in pre-warmed PBS plus 0.1% BSA at a final concentration of 
1 × 107 cells/mL, and 2 μL of 5 mM stock Cell Trace CFSE solution 
(Molecular Probes, USA) were added per 1 mL of the cells (final 
working concentration: 10 mM). After that, cells were incubated 
at 37°C for 10 min. Staining was quenched by adding 5 mL of 
ice-cold RPMI 1640 plus 10% FBS for 5 min on ice. The cells were 
washed three times at 300 × g, 7 min. For the mitogenic stimulus 
assays, 25-μL aliquots of PBMCs (2.5 × 105 cells/well) were added 
to triplicate wells with 25  μL of phytohemagglutinin (2.5  μg/
mL; Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
and incubated in a humidified 5% CO2 atmosphere at 37°C for 
3 (mitogenic-stimulated cultures) or 5 days (antigen-stimulated 
cultures). In order to investigate the immunophenotypic features, 
PBMCs were cultured in 48-well flat-bottomed tissue culture 
plates (Costar, Cambridge, MA, USA), with each well contain-
ing 650 μL of supplemented RPMI medium. Aliquots (50 μL) of 
PBMCs (5.0 × 105 cells/well) were added to triplicate wells with 
100 μL of SLiAg (25 μg/mL) or 100 μL of RPMI 1640 as control. 
Incubation was carried out in a humidified 5% CO2 atmosphere at 
37°C for 5 days. Afterward the cells were removed, washed twice 
with PBS, and stained at room temperature for 30 min in the dark 
with anti-CD4 PE (clone YKIX302.9), anti-CD8 AF647 (clone 
YCATE55.9), all purchased from Serotec, USA. After that, the 
cells were washed two times at 300 × g for 10 min, resuspended, 
and fixed in FACS fixing solution (10  g/L paraformaldehyde, 
10.2 g/L sodium cacodylate, and 6.63 g/L sodium chloride, pH 
7.2) before being run on the flow cytometer (FACScalibur—
Becton Dickinson, San Jose, CA, USA).
Immunostaining for cell surface markers and intracellular 
cytokine assay were performed as previously published (34). 
Briefly, two polypropylene tubes were prepared for each animal; 
one as a control tube (1 mL RPMI plus 1 mL of whole blood in 
heparin), and the second one was the antigen-stimulated tube, 
using SLiAg at final concentration of 25 μg/mL. The tubes were 
incubated for 12 h and kept at 37°C in an incubator with 5% CO2. 
Brefeldin A (BFA) (Sigma, St. Louis, MO, USA) was added to each 
tube at a final concentration of 10 μg/mL, and cultures were then 
incubated to an additional 4 h in an incubator with 5% CO2 at 
37°C. A tube containing PMA at a final concentration of 25 ng/
mL was used as a positive control at final 4 h of incubation as 
BFA. First staining was performed for monoclonal anti-surface 
molecules (CD4+ and CD8+). After resuspension, we proceeded 
to stain for intracytoplasmic cytokines anti-IFN-γ (clone CC302) 
and anti-IL-4 (clone CC303) (Serotec Ltd., Oxford, England) in 
U-bottom 96-well plates. The microtubes were kept at 4°C until 
the acquisition of counts on the flow cytometer (FACScalibur—
Becton Dickinson, San Jose, CA, USA), which evaluated at least 
30,000 events per tube. Final data of proliferation and intracyto-
plasmic cytokine production assays were expressed as indexes, 
calculated by dividing the percentage of positive cells observed 
in the SLiAg-stimulated culture by the one observed in paired 
control unstimulated culture (SLiAg/CC ratio).
TnF-α and il-10 Quantification
Cytokine quantification in culture supernatants from PBMCs 
was performed by capture ELISA using mouse monoclonal anti-
canine TNF-α and IL-10 antibodies (mAb) and biotinylated poly-
clonal goat anti-canine TNF-α and IL-10 (R&D Systems, USA). 
Wells of 96-well plates (Maxisorb, Nalgene Nunc International, 
Rochester, NY, USA) were coated with 1.0  μg/mL mAb for 
cytokine capture. The detection antibodies were used at 1.5 μg/
mL. Recombinant canine TNF-α and IL-10 (R&D Systems, USA) 
were used to generate standard curves. The test reactivity was 
detected with 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich, 
USA) in accordance with the manufacturer’s instructions. The 
assays were read on an automatic EL 800G ELISA microplate 
reader (Bio Tek Instruments, Winooski, VT, USA) with a 450 nm 
filter.
clinical Parameters
We assessed the dogs for clinical signs of VL at each examination 
comparing before treatment (T0) and after 90  days of treat-
ment (T90). We analyzed systemic signs (lymphadenopathy, 
apathy, arthritis, and diarrhea) cutaneo-mucosal signs [alopecia, 
hyperkeratosis, seborrhea, pyodermatitis, ulcers, vasculitis, 
depigmentation, onychogryphosis, skin erythema, hair loss, 
and nodule(s)], and ocular signs (conjunctivitis and keratitis). 
Moreover, the body weight of dogs was evaluated before and after 
the immunotherapy.
For the clinical score construction, the parameters were clas-
sified according to severity on a scale from 0 to 3, as follows: 0, 
absent; 1, mild; 2, moderate, and 3, severe. The sum of the clinical 
score was calculated by adding the points given to each of the 17 
listed clinical parameters at each examination time. After that, 
we evaluated the reduction observed after immunotherapy and 
transformed these values into percentage. The reduction in the 
clinical score means that there was a decrease in the number and 
intensity of the clinical signs.
In order to evaluate the splenomegaly, the dogs were submit-
ted to general anesthesia using the combination of 2 mg/kg of 
xylazine chloridrate (Calmium; União Química Farmacêutica 
S/A, Brazil) and 11  mg/kg of ketamine chloridrate (Agener; 
União Química Farmacêutica S/A, Brazil) by intramuscular 
injection. After that, the spleen was studied with portable 
ultrasound equipment (SonoSite SonoHeart Elite Superior 180 
Plus; SonoSite Inc., USA), and the thickness of the organ was 
measured. The alterations observed in the spleen were classified 
from normal spleen to presenting mild, moderate, or severe 
splenomegaly.
TaBle 1 | WBc of dogs naturally infected by L. infantum before and after 
immunotherapy.
WBc (/mm3) normal range Timeline after 
immunotherapy 
T0 T90
MPL Leukocytes 7,408–14,440 9,680 ± 2,275 10,800 ± 2,636
Neutrophils 3,839–9,379 5,353 ± 906 7,474 ± 2,886
Eosinophils 150–709.4 269 ± 129 670 ± 251a
Lymphocytes 2,299–5,119 2,703 ± 1,395 3,098 ± 360
Monocytes 147–601 251 ± 149 397 ± 211 
LBMPL Leukocytes 7,408–14,440 8,750 ± 2,162 9,886 ± 2,060
Neutrophils 3,839–9,379 5,585 ± 1,814 5,696 ± 1,523
Eosinophils 150–709.4 295 ± 281 189 ± 86*
Lymphocytes 2,299–5,119 2,765 ± 586 2,815 ± 565 
Monocytes 147–601 200 ± 107 364 ± 113
Absolute values (mean ± SD) of the white blood cells (WBC) count of dogs naturally 
infected by Leishmania infantum before and after receiving immunotherapy with LBMPL 
vaccine and/or MPL adjuvant alone. Significant differences (P < 0.05) are represented 
by the letter “a” related to time T0. The “*” denotes a significant difference (P < 0.05) 
between groups LBMPL and MPL at T90.
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Xenodiagnosis
Xenodiagnosis was performed as previously described (36) with 
some modifications, in order to verify the ability of treated dogs 
to infect the sand flies. Briefly, just before treatment—T0 and 
90  days after concluding the immunotherapy (T90), animals 
were submitted to general anesthesia, and the internal surface 
of the right ear was shaved. Forty to fifty 4-day-old females of 
Lutzomyia longipalpis were placed in a FleboContainer (37) and 
allowed to feed on the right ear for 30 min in a dark room. After 
the blood meal, the sand flies were fed daily with a 50% fructose 
solution and kept at 25°C for 5 days. At the end of 5 days, the 
sand flies were frozen, and females were grouped into pools of 10 
specimens and stored at −20°C until DNA extraction.
Quantification of Parasites in Bone 
Marrow, skin, and sand Flies
Parasite load was evaluated using quantitative real-time PCR (qPCR) 
in bone marrow, skin, and sand flies before (T0) and 90 days (T90) 
after treatment. Total DNA extraction of the samples was carried out 
using Wizard SV Genomic DNA Purification System Kit (Promega 
Corporation, USA) according to the manufacturer’s instructions. The 
pools of 10 females of sand flies were submitted to DNA extraction 
as previously described (38). In order to quantify parasite burdens, 
primers (forward, 5′ TGT CGC TTG CAG ACC AGA TG 3′ and 
reverse, 5′ GCA TCG CAG GTG TGA GCA C 3′) that amplified 
a 90-bp fragment of a single-copy gene of DNA polymerase of L. 
infantum (GenBank accession number AF009147) was used in a 
TaqMan system (39). Standard curves were prepared for each run 
using known quantities of pGEM®-T plasmids (Promega, USA) con-
taining inserts of interest. qPCR reactions were carried out with a final 
volume of 25 μL of mixture containing 1× TaqMan Universal Master 
Mix (Applied Biosystems), 20 pmol of the specific primers, 10 pmol of 
the labeled probe, and 20 ng of DNA. The thermal cycling conditions 
included an initial incubation for 2 min at 50°C, followed by a 10-min 
denaturation at 95°C, and 40 cycles at 95°C for 15 s and 60°C for 1 min 
each. The standard and samples were analyzed in duplicate for each 
run. To verify the integrity of the bone marrow and skin samples, the 
same procedure was carried out for GAPDH gene (AB038240) that 
amplified a 115-bp fragment. The L. longipalpis periodicity gene that 
amplified an 80-bp fragment (GenBank accession no: AF446142) 
(40) was used with the same procedure to verify the integrity of sand 
flies’ samples. Reactions were processed and analyzed in an ABI 
Prism 7500-Sequence Detection System (Applied Biosystems, USA). 
The results were expressed as the number of amastigotes per milliliter 
of bone marrow, per microgram of skin or number of promastigotes 
per dog (total promastigotes in pools of sand flies/dog).
statistical analysis
Statistical analyses were performed using Prism 5.0 software 
package (Prism Software, Irvine, CA, USA). Normality of the 
data was demonstrated using a Kolmogorov–Smirnov test for 
immunophenotypic profiles (ex vivo), cytokine production, 
intracytoplasmatic cytokine, and clinical evaluation. Data were 
analyzed for statistical differences using paired t-test. The results 
of proliferation response and parasite burden were considered, 
according to the Kolmogorov–Smirnov test, not normally 
distributed, and the Wilcoxon test and Mann–Whitney test were 
used. In all cases, the two-tailed P value was used, and the dif-
ferences were considered significant when P values were <0.05.
resUlTs
immunotherapy with lBMPl Vaccine 
shows normalization of the Biochemical 
and hemogram in infected Dogs and an 
increase in T cells, nK cells, and 
Monocytes
Based on the hemogram evaluation, WBC did not show 
important modifications in both groups of dogs, MPL and 
LBMPL before (T0) and 90 days after immunotherapy (T90) 
(Table 1). On the other hand, only the LBMPL-treated dogs 
demonstrated an entire normalization in RBC parameters 
with restoration of normal values of erythrocytes, hemo-
globin, hematocrit, and platelets (Table 2). The biochemical 
evaluation showed normalization in urea and creatinine 
(renal function) and GOT, ALP, and bilirubin (liver func-
tion) in LBMPL dogs after immunotherapy (Figure S1 in 
Supplementary Material).
In order to evaluate the immunophenotypic profile of the 
treated dogs in peripheral blood, we evaluated the frequency of 
T lymphocytes (CD3+) and their major subpopulations (CD4+ 
and CD8+) (Figures  1A–C). Our results revealed an increase 
(P < 0.05) in the number of circulating CD3+ T lymphocytes in 
dogs treated with LBMPL at T90 compared with T0 (Figure 1A). 
Moreover, we observed an increase (P < 0.05) in the number of 
circulating CD8+ T lymphocytes in dogs of LBMPL at T90 when 
compared with T0 and reduced number (P < 0.05) of these cells 
in MPL dogs at T90 when compared with T0 (Figure  1C). In 
addition, we observed a relevant increase (P < 0.05) in NK cells 
after treatment (T90) in LBMPL dogs compared with MPL group 
FigUre 1 | Profile of peripheral blood leukocytes in dogs naturally infected by Leishmania infantum after immunotherapy with lBMPl vaccine or 
with MPl adjuvant alone. The immunophenotyping of peripheral blood was used to characterize the systemic cellular profile of circulating leukocytes in dogs 
submitted to immunotherapy with LBMPL vaccine (black rectangle) or MPL adjuvant alone (white rectangle), before (T0) and after 90 days (T90) of treatment. Data 
are reported as number of leukocytes in cubic meters of blood. Results are expressed as mean values ± SD of T cells (CD3+) (a) and subpopulations CD4+ (B) and 
CD8+ (c), B cells (CD21+) (D), NK cells (CD5−CD16+) (e), and monocytes (CD14+) (F). Significant differences (P < 0.05) are shown by connecting line—representing 
differences between the LBMPL and MPL groups—and by the “*”—representing differences between T0 and T90.
TaBle 2 | rBc of dogs naturally infected by L. infantum before and after 
immunotherapy.
erythrogram normal range Timeline after 
immunotherapy
T0 T90
MPL Erythrocytes (106/mm3) 5.42–8.38 6.0 ± 1.6 5.3 ± 0.8
Hemoglobin (g/dL) 13.2–21.2 12.8 ± 3.7 12.1 ± 2.2 
Hematocrit (%) 33.7–57.3 35.2 ± 9.1 31.8 ± 4.5
Platelets (103/mm3) 171–384 135 ± 13 113 ± 46
LBMPL Erythrocytes (106/mm3) 5.42–8.38 4.5 ± 0.6 6.1 ± 1.1a
Hemoglobin (g/dL) 13.2–21.2 11.0 ± 2.2 14.6 ± 2.4
Hematocrit (%) 33.7–57.3 32.1 ± 6.2 37.6 ± 6
Platelets (103/mm3) 171–384 148 ± 45 214 ± 45*
Absolute values (mean ± SD) of the red blood cells (RBC) count of dogs naturally 
infected by Leishmania infantum before and after receiving immunotherapy with 
LBMPL vaccine and/or MPL adjuvant alone. Significant differences (P < 0.05) are 
represented by the letter “a” related to time T0. The “*” denotes a significant difference 
(P < 0.05) between groups LBMPL and MPL at T90. Values in “red” represent values 
below the normal range.
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and with T0 (Figure  1E). Similarly, LBMPL animals showed a 
significant reduction (P < 0.05) in CD21+ B lymphocytes at T90 
compared with MPL group and compared with T0 (Figure 1D). 
When we evaluated the levels of potential antigen-presenting 
cells, only dogs treated with the LBMPL vaccine demonstrated 
higher number (P < 0.05) of circulating CD14+ monocytes at T90 
compared with T0 (Figure 1F).
lBMPl immunotherapy Triggers an 
intense In Vitro cell Proliferation and 
secretion of cytokines in the Presence of 
antigenic stimuli
To explore the effects of LBMPL immunotherapy on in vitro cell 
proliferation, we measured lymphoproliferative activation of 
PBMCs after immunotherapy (Figure 2A). Comparative analysis 
of the different treatment groups showed a significant increase 
(P <  0.05) in the lymphocyte proliferation in LBMPL dogs at 
T90 compared with T0. In addition, SLiAg-T-CD4+ proliferation 
was observed only in the LBMPL group with a higher (P < 0.05) 
lymphoproliferative ratio at T90 compared with before treatment 
(T0) (Figure 2A). Moreover, the most significant lymphoprolif-
erative activation was observed in SLiAg-T-CD8+ lymphocytes in 
LBMPL animals (P < 0.05) when compared with MPL group at 
T90 and compared with T0 (LBMPL) (Figure 2A).
In addition to the cell proliferation profile, we evaluated 
the cytokines produced by the PBMCs after SLiAg stimuli 
(Figure  2B). Interestingly, TNF-α showed higher levels in the 
LBMPL dogs before (T0) and after treatment (T90) when com-
pared with the MPL group (P < 0.05). Besides that, after treatment 
(T90), LBMPL animals showed higher levels (P < 0.05) of TNF-α 
FigUre 2 | Profile of lymphocyte proliferation and cytokine production in peripheral blood mononuclear cells (PBMcs) of dogs naturally infected by 
Leishmania infantum after immunotherapy with lBMPl vaccine or with MPl adjuvant alone. The lymphocyte proliferation response and cytokine 
production were evaluated in PBMCs after in vitro stimulation with soluble Leishmania infantum antigen (SLiAg) in dogs submitted to immunotherapy with LBMPL 
vaccine (black rectangle) or MPL adjuvant alone (white rectangle); before (T0) and after 90 days (T90) of treatment. Lymphocyte proliferation (a) and cytokine 
production (B) indexes were calculated as the proportion of lymphocyte, T-CD4+ and T-CD8+ proliferation (a) and IL-10 and TNF-α cytokine production (B) observed 
in SLiAg-stimulated cultures divided by the control culture (SLiAg/CC ratio). The results of lymphocyte proliferation are expressed by median, and the results of 
cytokine production are expressed by mean. Significant differences (P < 0.05) are shown by connecting lines–representing differences between the LBMPL and 
MPL groups—and by the “*”—representing differences between T0 and T90.
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when compared with the T0 (Figure 2B). On the other hand, the 
LBMPL dogs presented lower levels of IL-10 than MPL group 
(P < 0.05) at T90 (Figure 2B). Furthermore, expressive reduction 
in the levels of IL-10 (P < 0.05) was observed in LBMPL dogs at 
T90 when compared with T0 (Figure 2B).
high intracytoplasmic synthesis of iFn-γ+ 
by lymphocyte subsets (cD4+ and cD8+) 
after In Vitro antigen-specific stimulation 
is a Marker of immune restoration 
Promoted by lBMPl immunotherapy
In order to evaluate the cytokine profile produced by T-lymphocyte 
subsets, the intracytoplasmic synthesis of IFN-γ and IL-4 was 
assessed after antigen-specific stimulation (Figure  3A). In 
CD4+ lymphocytes, we observed reduction in IL-4 production 
(P < 0.05) in LBMPL dogs when compared with MPL group at 
T90. On the other hand, CD4+ lymphocytes showed an increase 
in the IFN-γ production at T90 in LBMPL dogs when compared 
with MPL group. Furthermore, we observed higher numbers 
of CD4+IFN-γ+ lymphocytes at T90 in LBMPL group when 
compared with the time before treatment (T0) (Figure 3B). Based 
on CD8+ lymphocytes analysis, we observed higher numbers of 
CD8+IFN-γ+ cells (P < 0.05) in LBMPL dogs when compared with 
MPL group at T90 and compared with T0 (LBMPL) (Figure 3C).
We also evaluated the IFN-γ/IL-4 ratio of the T-lymphocyte 
subsets and that was higher (P < 0.05) in LBMPL dogs than in 
the MPL group at T90 for both, CD4+ and CD8+ lymphocytes 
(Figures 3B,C). Similarly, there was a consistent higher IFN-γ/
IL-4 ratio in LBMPL group (P < 0.05) after treatment (T90) when 
compared with T0 (Figures 3B,C).
lBMPl immunotherapy leads to an 
important Parasite reduction in Bone 
Marrow and skin with Block Transmission 
after Xenodiagnosis
The main parasitological features presented by all animals are 
summarized in Figure 4. As shown in Figure 4A, low number 
(P < 0.05) of amastigotes was observed in the bone marrow of 
LBMPL group when compared with MPL dogs at T90. Moreover, 
this number of parasites was lower (P < 0.05) compared with the 
FigUre 3 | Profile of intracytoplasmatic cytokines in peripheral blood mononuclear cells (PBMcs) of dogs naturally infected by Leishmania infantum 
after immunotherapy with lBMPl vaccine or with MPl adjuvant alone. Pseudocolor plots illustrating the analysis of intracellular cytokines+ (IL-4 and IFN-γ) 
(a) in CD4+ cells (B) and CD8+ cells (c) within gated lymphocytes in PBMCs after in vitro stimulation with soluble Leishmania infantum antigen (SLiAg) in dogs 
submitted to immunotherapy with LBMPL vaccine (black rectangle) or MPL adjuvant alone (white rectangle); before (T0) and after 90 days (T90) of treatment. The 
frequency of cytokines+ T-cell subsets were calculated by quadrant statistics approach and first reported as percentage of gated lymphocytes prior to the calculation 
of the SLiAg/control indexes. The CD4+ and CD8+ cytokine indexes (B,c) were calculated as the proportion of cytokine+ cells observed in SLiAg-stimulated cultures 
divided by the control culture (SLAg/CC ratio). Significant differences (P < 0.05) are shown by connecting lines—representing differences between the LBMPL and 
MPL groups—and by the “*”—representing differences between T0 and T90.
FigUre 4 | Quantification of parasite burden in bone marrow, skin, and sand flies of dogs naturally infected by Leishmania infantum after 
immunotherapy with lBMPl vaccine or with MPl adjuvant alone. The parasite burden was performed to evaluate the curative properties of LBMPL vaccine 
(black and white squares) or MPL adjuvant alone (white circle); before (T0) and after 90 days (T90) of treatment. The number of amastigotes was estimated in bone 
marrow (a), skin (B), and sand flies (c). Results were plotted representing individual values of each dog per group with connecting lines of T0 and T90. Significant 
differences (P < 0.05) are shown by “#”—representing difference between the LBMPL and MPL groups—and by the “*”—representing differences between T0  
and T90.
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FigUre 5 | evaluation of clinical outcome [visceral leishmaniasis (Vl) signs], clinical score, body weight, and splenomegaly of dogs naturally 
infected by Leishmania infantum after immunotherapy with lBMPl vaccine or with MPl adjuvant alone. (a) Percentage of dogs with suggested VL signs 
submitted to immunotherapy with LBMPL vaccine (right) or MPL adjuvant alone (left), before (T0 = black rectangle) and after 90 days (T90 = white rectangle) of 
treatment. (B) Representative graph of the percentage of reduction of clinical score in dogs submitted to immunotherapy with LBMPL vaccine (black square) or MPL 
adjuvant alone (white circle), before (T0) and after 90 days (T90) of treatment. (c) Percentage of gain weight in dogs submitted to immunotherapy with LBMPL 
vaccine (black rectangle) or MPL adjuvant alone (white rectangle), before (T0) and after 90 days (T90) of treatment. (D) Percentage of animals classified according to 
the absence of splenomegaly (normal = white rectangle), mild splenomegaly (light gray), moderate (medium gray), and severe (dark gray); in dogs submitted to 
immunotherapy with LBMPL vaccine (right) or MPL adjuvant alone (left), before (T0) and after 90 days (T90) of treatment. Significant differences (P < 0.05) are shown 
by connecting lines—representing differences between the LBMPL and MPL groups—and by the “*”—representing differences between T0 and T90.
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time before treatment (T0) in the LBMPL dogs (Figure 4A). When 
we evaluated the skin, only LBMPL group showed an important 
reduction (P < 0.05) in the number of amastigotes at T90 when 
compared with T0 (Figure  4B). Moreover, when we assessed 
the parasite transmission to sand flies through xenodiagnosis, the 
LBMPL group induced an important reduction (P < 0.05) in the 
capacity to infect sand flies after treatment (T90) when compared 
with before treatment (T0). Furthermore, in the LBMPL group, 
six of nine dogs showed parasites after xenodiagnosis at T0. On 
the other hand, only three dogs demonstrated parasites after 
xenodiagnosis at T90. These data are associated with a negative 
detection of parasites in 33, 44, and 67% in LBMPL dogs in bone 
marrow, skin, and sand flies, respectively (data not shown).
Vl Dogs exhibit clinical improvement and 
reduction of splenomegaly after 
immunotherapy with lBMPl Vaccine
Before treatment—T0, all animals presented several clinical signs 
of CVL, and these signs were used as inclusion criteria. Figure 5A 
showed the main signs of CVL presented before (T0) and after 
(T90) the LBMPL and MPL treatment. In MPL dogs, we observed 
a disease progression with increase of the signs of CVL such as, 
seborrheic dermatitis, alopecia, pyodermatitis, skin erythema, 
depigmentation, apathy, conjunctivitis, nodules, and arthritis 
(Figure 5A). On the other hand, in dogs submitted to LBMPL 
immunotherapy, we observed reduction on signs of CVL such 
as, lymphadenomegaly, seborrheic dermatitis, hyperkeratosis, 
and alopecia. Moreover, many clinical signs of disease were not 
observed after LBMPL treatment, for example, pyodermatitis, skin 
erythema, apathy, hair loss, nodules, and diarrhea (Figure 5A). 
Dogs in the LBMPL-treated group presented a general improve-
ment in their clinical score with reduction of intensity and number 
of CVL signs with a percentage of reduction of 75% (Figure 5B). 
In contrast, the dogs of the MPL group presented an aggravation 
of the clinical status during all treatment period with only 1% of 
reduction of their clinical score and one dog from the MPL group 
died due to cachexia (Figure  5B). Besides that, we observed a 
body weight gain (P < 0.05) in the LBMPL dogs after treatment 
(T90) compared with T0 (Figure  5C). On the other hand, the 
MPL group showed a significant reduction (P <  0.05) of body 
mass at T90 suggesting progression of disease (Figure 5C). Using 
ultrasound equipment, we evaluated the spleen size in MPL and 
LBMPL dogs at T0 and after immunotherapy (T90). As shown in 
Figure 5D before the LBMPL immunotherapy, 70% of the dogs 
exhibited moderate/severe splenomegaly. After treatment, we 
observed a strong reduction of this alteration with only 30% of 
animals presenting moderate/severe splenomegaly. In contrast, 
MPL dogs showed an increase in moderate/severe splenomegaly 
ranging from 20% before treatment to 80% after treatment.
Figure  6 shows representative examples of CVL signs of 
both groups, MPL and LBMPL, before (T0) and after treatment 
(T90). LBMPL immunotherapy promoted a substantial clinical 
improvement in dogs when compared with the MPL group as 
FigUre 6 | clinical efficacy of dogs naturally infected by Leishmania infantum after immunotherapy with lBMPl vaccine or with MPl adjuvant 
alone. Illustrative images of dogs submitted to immunotherapy with MPL adjuvant alone (a) or LBMPL vaccine (B), before (T0) and after 90 days (T90) of treatment.
10
Roatt et al. Vaccine Therapy for CVL
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 217
shown by the dogs in Figure  6B. Most of the LBMPL-treated 
animals showed significant clinical improvement with some dogs 
demonstrating complete remission of clinical signs suggestive of 
VL (Figure 6B). On the other hand, animals treated with MPL 
alone got worse their VL symptoms during and at the end of the 
study (Figure 6A) At the end of study, we observed that 78% (7/9) 
of LBMPL-treated dogs showed significant clinical improvement 
in relation to the signs and symptoms suggestive of VL. On the 
other hand, 100% (5/5) of the dogs treated with MPL showed 
no clinical remission of signs progressing gradually toward the 
disease.
DiscUssiOn
A current problem that has worsened the situation of VL in the 
world is associated with the large number of non-responders 
patients to conventional chemotherapy with antimony, suggesting 
the emergence of resistant strains of the parasite (41). For this rea-
son, there is a regional variation in the response to treatment in VL 
patients, and recommendations for the use of conventional drugs 
may vary in different regions of the world (42). In this sense, the 
use of therapeutic vaccines and other immunobiological agents 
has attracted attention in the treatment for leishmaniasis. This 
strategy, known as immunotherapy, uses biological substances 
and/or immunobiological agents that act to modulate or modify 
the immune response in order to achieve a prophylactic and/or 
therapeutic objective (43). The immunotherapeutic agents may 
exert their effect by direct or indirect action increasing the natural 
defenses and restoring the disabled effectors function.
In the present work, we conducted a detailed analysis of an 
immunotherapy protocol using the LBMPL vaccine as potential 
treatment for VL, using symptomatic dogs naturally infected by L. 
infantum as experimental model. We evaluated the main hemato-
logical changes and blood leukocytes profile in dogs submitted to 
immunotherapy with LBMPL vaccine as well as the group treated 
with MPL adjuvant only. As observed, important normalization 
in RBC with restoration of erythrocytes, hemoglobin, hematocrit, 
and platelets was achieved after immunotherapy. Moreover, after 
blood evaluation, the immune profile observed in treated dogs 
showed an increase in CD3+ T cells represented mainly by CD8+ 
T-cell subpopulation, increase in NK cells and CD14+ monocytes 
and decrease in B-cells. Patients with active and severe VL exhibit 
a blood marker anemia with decreased values of hemoglobin and 
hematocrit and low counts of platelets (44). For both, human and 
dogs, the decline of these parameters indicates an adverse prog-
nosis. As we observed, the immunotherapy with LBMPL vaccine 
promoted normalization in these biomarkers. Furthermore, 
restoration of the circulating leukocytes, mainly the specific T 
cells and monocytes, reinforces a beneficial nature of the immu-
notherapeutic treatment performed. Many studies using vaccines 
and other immunomodulators show that the restoration of 
circulating T lymphocytes with others cells is essential to clinical 
improvement and control of parasitism (24, 45, 46).
The activation and enhancement of an effective cell immune 
response are the challenges associated with severe VL. In our study, 
we evaluated whether the immunotherapy with LBMPL would 
activate PBMCs after in vitro antigenic stimulation with SLiAg. 
Our results showed that higher cell reactivity after stimulation 
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with SLiAg was recorded in the LBMPL-treated dogs accom-
panied by increased lymphoproliferation. Also, this increase 
was marked by both specific CD4+ and CD8+ L. infantum-T 
lymphocytes. The positive lymphoproliferative immune response 
against the Leishmania antigen is a classic marker of resistance in 
both canine and human disease (15, 47–49). It has been reported 
that naturally infected dogs presenting no clinical signs showed 
98% of positive correlation between intradermal response (IDR) 
and in vitro lymphoproliferative activation (50). In some patients 
with diffuse cutaneous leishmaniasis was observed a positive IDR 
with Leishmania antigens after immunotherapy with pasteur-
ized L. braziliensis vaccine plus BCG and, even 10 months after 
treatment, all those patients presented remission of symptoms 
indicating clinical cure against the disease (51). Associated with 
in vitro lymphoproliferative response, we observed a strong TNF-
α production with low levels of IL-10, an immunomodulatory 
cytokine. These results confirm the effect promoted by LBMPL 
immunotherapy activating a pro-inflammatory cell immune 
response consistent with the development of a protective immu-
nity against the disease.
Considering the combined analysis of T-cell subpopulations 
and cytokine production, both CD4+ and CD8+ T cells are rel-
evant sources of IFN-γ after treatment with LBMPL vaccine. On 
the other hand, these cells did not produce or secrete IL-4. As 
shown classically, the increased production of IFN-γ is critical for 
parasitism control through microbicidal activity of macrophages 
(52). Regarding IL-4, it has been suggested that this cytokine acts 
by inhibiting transduction of signals for inducible nitric oxide 
synthase reducing the NO production by macrophages (53). In a 
VL murine model, the immunotherapy using liposomal resiqui-
mod promoted an increase in IFN-γ levels and as consequence, 
the tissue parasitism control (54). Dealing with the natural infec-
tion, it is observed in asymptomatic dogs a resistant immune 
profile characterized by high levels of both IFN-γ and TNF-α and 
low levels of IL-10 (55). As described elsewhere, after successful 
VL treatment patients gradually regain their cells capacity to 
produce IFN-γ, but not IL-10 after specific Leishmania stimuli 
(56). In this context, our results suggest that immunotherapy 
with LBMPL vaccine was able to promote in the dogs a consistent 
immune activation with production of inflammatory cytokines 
(IFN-γ and TNF-α) and low production of immunomodulatory 
cytokines characterizing a control profile of the disease.
Following treatment with LBMPL vaccine, dogs demonstrated 
a pronounced improvement of clinical signs and in the clinic 
pathological abnormalities. Moreover, the improvement observed 
in LBMPL dogs was gradual and included complete regression or 
marked reduction in the number and degree of skin alterations, 
weight gain, reduction and/or absence of lymphadenopathy, res-
toration in the color of the mucous membranes, and regression in 
the eye lesions. This reduction of clinical signs in dogs represented 
75% decrease in the clinical score in dogs of LBPML group and 
some animals presenting no CVL alterations with total clinical 
cure at the final of the experiment. The use of an ultrasound 
device helped with the splenomegaly evaluation and we observed 
a normalization of the spleen size in more than 60% of LBMPL-
treated dogs compared with MPL control animals (only 20%). 
Furthermore, dogs submitted to immunotherapy with LBMPL 
vaccine showed no signs of pain at the site of injection and no side 
effects. Miret et al. (22) using a vaccine combined with MPL-SE 
(Leish-110f®  +  MPL-SE®) in dogs observed improvement in 
clinical response after immunotherapy. On the other hand, when 
MPL-SE® was used, dogs got worse their symptoms during and 
at the end of the study (22). Using a protein aggregate magne-
sium–ammonium phospholinoleate–palmitoleate anhydride 
immunomodulator (P-MAPA), Santiago et al. (24) observed an 
intense improvement in clinical signs of dogs submitted to this 
immunotherapy. On the other hand, as observed in our study, 
clinical signs worsened in control group with dogs presenting 
intense loss of weight, anorexia, and cachexia (24). Regarding 
human VL, pioneering studies conducted by Badaro et al. (15) 
evaluating immunochemotherapy protocol with meglumine 
antimoniate and IFN-γ in patients with therapeutic failure and/
or severe VL showed 90% of clinical cure after treatment. These 
authors suggest that the high rates of clinical cure achieved were 
largely due to immunotherapy protocol used (15).
Often, clinical improvement observed in treated animals and 
patients with VL is accompanied by parasitism reduction. In our 
study, we evaluated the parasite burden in bone marrow, skin, 
and sand flies after xenodiagnosis using the qPCR. As observed, 
dogs immunotreated with LBMPL vaccine presented an intense 
parasite reduction in both bone marrow and skin before and 
after treatment. da Silva et al. (36) evaluating a combined therapy 
using liposomal meglumine antimoniate and allopurinol in 
VL dogs, observed a significant reduction in the parasite load 
at spleen and liver after treatment. Similarly, Manna et al. (57) 
observed reduction in parasite load in the spleen and lymph 
nodes following administration of miltefosine in combination 
with allopurinol in CVL animals. Similar results were obtained 
by Miret et  al. (22) using conventional parasitological tests 
(smear and culture) to evaluate immunotreated dogs. All dogs 
treated with vaccine had negative parasitological tests. On the 
other hand, the control adjuvant group (MPL-SE®) presented 
positive parasitological tests in all dogs in bone marrow and skin 
(22). Evaluating the skin, the most important tissue and source 
of parasite transmission to the vectors, we observed a significant 
decrease in parasite load in LBMPL-treated dogs with 127 times 
lower parasite burden compared with the time before treatment. 
As discussed by some authors, one of the most important objec-
tives of the CVL treatment is the blockade of transmission to 
sand flies by reducing the parasite load in the skin concomitantly 
with decrease of the disease and remission of symptoms (58). 
Therefore, we evaluated the ability of the LBMPL-treated dogs 
to infect sand flies by xenodiagnosis. It is possible to observe in 
our study that LBMPL vaccine therapy was capable to promote a 
significant reduction in the parasite infection to sand flies. Thus, 
both the skin parasite load and xenodiagnosis results showed that 
the immunotherapy with LBMPL vaccine was effective, control-
ling the parasite burden in the skin associated with reduction 
transmission to L. longipalpis.
As observed in some studies, depending on the clinical condi-
tion of human patients and dogs, the use of chemotherapy is inef-
ficient (59, 60), and the association of immunomodulators and or 
vaccines would promote an effective cellular immune response 
controlling the parasite proliferation. As noted in our study, the 
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immunotherapy using LBMPL vaccine in symptomatic VL dogs 
promoted the normalization of hematological and biochemical 
parameters, the restoration, activation, and polarization of the 
immune response with a protective profile, clinical improvement, 
and intense reduction in the parasite burden with potential to 
block transmission to sand flies. The encouraging results pre-
sented here reinforce the relevance of previous studies in CVL 
that can indicate immunotherapy as significant approach to be 
used as potential treatment strategy. Our work can be seen as a 
subsidy for future studies to evaluate the use of LBMPL combined 
with other leishmanicidal drugs (immunochemotherapy), aiming 
the reduction of (i) administration period, (ii) dose of the drug 
required, and (iii) side effects. Based on that, it will be possible to 
analyze if this combination can promote more effectively clinical 
and parasitological cure in VL.
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